首页> 美国卫生研究院文献>other >Phase I/II Randomized Trial of Sorafenib and Bevacizumab as First-Line Therapy in Patients with Locally Advanced or Metastatic Hepatocellular Carcinoma: North Central Cancer Treatment Group trial N0745 (Alliance)

【2h】

Phase I/II Randomized Trial of Sorafenib and Bevacizumab as First-Line Therapy in Patients with Locally Advanced or Metastatic Hepatocellular Carcinoma: North Central Cancer Treatment Group trial N0745 (Alliance)

机译：索拉非尼和贝伐单抗的I / II期随机试验作为局部晚期或转移性肝细胞癌患者的一线治疗：北中部癌症治疗组试验N0745（联盟）

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

摘要
著录项
相似文献
相关主题

摘要

BackgroundAngiogenesis has been a major target of novel drug development in hepatocellular carcinoma (HCC). It is hypothesized that the combination of two antiangiogenic agents, sorafenib and bevacizumab, will provide greater blockade of angiogenesis.

机译：背景血管生成已成为肝细胞癌（HCC）中新药开发的主要目标。假设两种抗血管生成剂索拉非尼和贝伐单抗的组合将提供更大的血管生成阻断作用。

著录项

期刊名称 other
作者
Joleen M. Hubbard; Michelle R. Mahoney; William S. Loui; Lewis R. Roberts; Thomas C. Smyrk; Zoran Gatalica; Mitesh Borad; Shaji Kumar; Steven R. Alberts;
展开▼
作者单位

展开▼
年(卷),期 -1(12),2
年度 -1
页码 201–209
总页数 18
原文格式 PDF
正文语种
中图分类
关键词

相似文献

外文文献
中文文献
专利

1. Phase I/II Randomized Trial of Sorafenib and Bevacizumab as First-Line Therapy in Patients with Locally Advanced or Metastatic Hepatocellular Carcinoma: North Central Cancer Treatment Group Trial N0745 (Alliance) [J] . Hubbard Joleen M., Mahoney Michelle R., Loui William S., Targeted oncology . 2017,第2期

机译：I / II阶段I / II随机试验Sorafenib和Bevacizumab作为局部晚期或转移性肝细胞癌患者的一线治疗：北中央癌症治疗组试验N0745（联盟）
2. A Phase III, Randomized, Double-Blind, Placebo-Controlled Trial of Pegfilgrastim in Patients Receiving First-Line FOLFOX/Bevacizumab or FOLFIRI/Bevacizumab for Locally Advanced or Metastatic Colorectal Cancer: Final Results of the Pegfilgrastim and Anti-VEGF Evaluation Study (PAVES) [J] . Pinter Tamas, Klippel Zandra, Cesas Alvydas, Clinical colorectal cancer . 2017,第2期

机译：在接受一线Folfox / Bevacizumab或Folfiri / BevacizumAb的患者中，PEGFILGRASIM的AII，随机，双盲，安慰剂对照试验，用于局部晚期或转移性结直肠癌：PEGFILGRASTIM和抗VEGF评估研究的最终结果（铺设）
3. Randomized phase IIIb trial evaluating the continuation of bevacizumab beyond disease progression in patients with advanced non-squamous non-small-cell lung cancer after first-line treatment with bevacizumab plus platinum-based chemotherapy: treatment rationale and protocol dynamics of the AvaALL (MO22097) trial. [J] . Gridelli C, Bennouna J, de Castro J, Clinical lung cancer . 2011,第6期

机译：IIIb期随机试验评估了贝伐单抗联合铂类化疗一线治疗后晚期非鳞状非小细胞肺癌晚期贝伐单抗在疾病进展中的延续性：AvaALL的治疗原理和方案动态（MO22097）试用。
4. Molecular Therapies in Hepatocellular Carcinoma beyond Sorafenib: Lessons from Failed Phase III Trials and Novel Targets [C] . Lipika Goyal, Andrew X. Zhu Gastrointestinal Cancers Symposium . 2014

机译：Sorafenib之外的肝细胞癌中的分子疗法：III期试验失败的课程和新型靶标
5. Recruitment, retention and compliance in randomized, phase III clinical trials involving obese patients diagnosed with type 2 Diabetes Mellitus with respect to weight loss practicum report. [D] . Mithani, Moez S. 2012

机译：涉及诊断为2型糖尿病的肥胖患者的有关减肥实践的随机III期临床试验中的招募，保留和依从性报告。
6. Randomized Phase III Trial of Paclitaxel Once Per Week Compared With Nanoparticle Albumin-Bound Nab-Paclitaxel Once Per Week or Ixabepilone With Bevacizumab As First-Line Chemotherapy for Locally Recurrent or Metastatic Breast Cancer: CALGB 40502/NCCTG N063H (Alliance) [O] . Hope S. Rugo, William T. Barry, Alvaro Moreno-Aspitia, -1

机译：每周一次紫杉醇与绑定纳米白蛋白的Nab-紫杉醇每周一次或与伊沙贝比隆联合贝伐单抗作为局部复发或转移性乳腺癌的一线化疗的随机III期试验：CALGB 40502 / NCCTG N063H（联盟）
7. Randomized Phase IIIb Trial Evaluating the Continuation of Bevacizumab Beyond Disease Progression in Patients with Advanced Non-Squamous Non–Small-Cell Lung Cancer after First-Line Treatment with Bevacizumab Plus Platinum-Based Chemotherapy: Treatment Rationale and Protocol Dynamics of the AvaALL (MO22097) Trial [O] . Gridelli Cesare, Bennouna Jaafar, de Castro Javier, 2011

机译：评估贝伐单抗联合铂类化学疗法一线治疗的晚期非鳞状非小细胞肺癌晚期贝伐单抗超越疾病进展的持续性的随机IIIb期试验：AvaALL的治疗原理和方案动态（MO22097）试用版

Phase I/II Randomized Trial of Sorafenib and Bevacizumab as First-Line Therapy in Patients with Locally Advanced or Metastatic Hepatocellular Carcinoma: North Central Cancer Treatment Group trial N0745 (Alliance)

摘要

著录项

相似文献

相关主题

期刊订阅